楊志平,張建成,林亞洲,陳建泉,吳梅瓊,連亮華,陳林
1.福建省立醫(yī)院心血管內(nèi)科,福建福州 350001;2.福建醫(yī)科大學(xué)省立臨床學(xué)院,福建福州 350001
CHA2DS2-VASc評(píng)分及MDCT對(duì)非瓣膜性房顫
患者左心房/左心耳血栓預(yù)測(cè)價(jià)值的臨床研究
楊志平1,2,張建成1,2,林亞洲1,2,陳建泉1,2,吳梅瓊1,2,連亮華1,2,陳林1,2
1.福建省立醫(yī)院心血管內(nèi)科,福建福州 350001;2.福建醫(yī)科大學(xué)省立臨床學(xué)院,福建福州 350001
目的 探討CHA2DS2-VASc評(píng)分及MDCT對(duì)Nonvalvular AF預(yù)行消融術(shù)患者左房/左心耳(LA/LAA)血栓形成預(yù)測(cè)價(jià)值。方法 整群選取2012年1月—2014年12月期間預(yù)行射頻消融術(shù)房顫患者233例,進(jìn)行CHA2DS2-VASc評(píng)分,經(jīng)食道心臟彩超及左心房MDCT檢查以排除左心房血栓。線性趨勢(shì)χ2檢驗(yàn)分析CHA2DS2-VASc評(píng)分與LA/ LAA血栓發(fā)生率關(guān)系。McNemar法χ2檢驗(yàn)驗(yàn)證左心房MDCT與傳統(tǒng)TEE技術(shù)一致性。結(jié)果 233入選病例中LA/LAA血栓形成13例,CHA2DS2-VASc評(píng)分0分組1例,1分組2例,2分組3例,3分組3例,≥4分組4例。0~1分組血栓發(fā)生率2.16%,3分以上為16.28%。線性趨勢(shì)χ2檢驗(yàn)分析提示CHA2DS2-VASc評(píng)分與LA/LAA血栓形成有明顯統(tǒng)計(jì)學(xué)意義,P=0.001。TEE法檢出血栓8例,左心房MDCT發(fā)現(xiàn)3例,McNemar法χ2檢驗(yàn)P=0.062,提示兩種方法一致性。結(jié)論CHA2DS2-VASc評(píng)分與LA/LAA血栓形相關(guān),評(píng)分越高血栓形成風(fēng)險(xiǎn)趨大,伴高血壓病、充血性心力衰竭是血栓形成主要危險(xiǎn)因素。CHA2DS2-VASc 0分、1分低危組預(yù)行消融術(shù)患者LA/LAA血栓形成發(fā)生率極低。左心房MDCT技術(shù)與傳統(tǒng)TEE檢查有較好一致性。
非瓣膜性房顫;CHA2DS2-VASc評(píng)分;左房/左心耳血栓形成;左心房螺旋CT檢查(MDCT);經(jīng)食管超聲心動(dòng)圖檢查(TEE)
心房顫動(dòng)(Atrial fibrillation,af)是臨床最常見(jiàn)心律失常,可導(dǎo)致腦卒中、血栓栓塞,具有較高致死、致殘率。目前國(guó)內(nèi)外心房顫動(dòng)處理指南推薦CHA2DS2-VASc評(píng)分系統(tǒng),用以評(píng)估房顫血栓、栓塞風(fēng)險(xiǎn),指導(dǎo)抗凝治療[1-2]。該研究立題于CHA2DS2-VASc評(píng)分系統(tǒng)在房顫消融術(shù)前評(píng)估中應(yīng)用價(jià)值,以TEE作為金標(biāo)準(zhǔn),納入福建省立醫(yī)院心血管內(nèi)科2012年1月—2014年12月期間因非瓣膜性房顫(Nonvalvular AF)預(yù)行射頻消融術(shù)房顫患者233例,系統(tǒng)評(píng)價(jià)CHA2DS2-VASc評(píng)分與非瓣膜性房顫患者左房/左心耳血栓形成相關(guān)性,并對(duì)左心房螺旋CT檢查(multidetector computed tomography, MDCT)技術(shù)檢查左心房、左心耳血栓應(yīng)用價(jià)值進(jìn)行對(duì)比研究。
整群選取預(yù)行射頻消融術(shù)房顫患者233例,其中陣發(fā)性房顫21例,持續(xù)性房顫22例,男性157例,女性76例(76/233,32.6%),平均年齡(57.82±9.44)歲。合并高血壓病106例,糖尿病史者32例,充血性心力衰竭14例,腦卒中/TIA病史9例,血管疾病者30例。經(jīng)體表心電圖或24小時(shí)動(dòng)態(tài)心電圖確診心房顫動(dòng)、排除風(fēng)濕性心臟瓣膜病及其他嚴(yán)重心臟瓣膜病變、擴(kuò)張型心肌病等非介入治療適應(yīng)癥病例。對(duì)于陣發(fā)性房顫CHDS2-VASc0分、1分病例僅于術(shù)前5~7 d低分子肝素抗凝并經(jīng)TEE、CTA排除血栓后即進(jìn)入消融治療,對(duì)于持續(xù)性、長(zhǎng)程持續(xù)性房顫患者則進(jìn)行4周以上標(biāo)準(zhǔn)華法林抗凝(INR2-3),術(shù)前1周停用華法林并予低分子肝素過(guò)渡經(jīng)TEE、CTA排除血栓后接受房顫消融術(shù)。進(jìn)行CHA2DS2-VASc評(píng)分,經(jīng)胸心臟超聲、經(jīng)食道超聲TEE、左心房MDCT檢查明確左房、左心耳血栓形成情況,并對(duì)比分析。經(jīng)書面知情同意后,進(jìn)入心腔內(nèi)電生理檢查及導(dǎo)管射頻消融術(shù)治療及后續(xù)隨訪觀察研究。研究通過(guò)該院倫理委員會(huì)批準(zhǔn)。
1.1 食道超聲心動(dòng)圖檢查(TEE)
GE Vivid.7型彩色多普勒血流顯像儀(美國(guó)通用電氣公司,Vivid7彩超機(jī)),多平面經(jīng)食道探頭,頻率2.7~5.4 MHz。見(jiàn)圖1。
圖1 經(jīng)食管超聲心動(dòng)圖檢查(transoesophagealechocardiography,TEE)
表1 不同CHA2DS2-VASc評(píng)分組間臨床特征
1.2 左心房MDCT檢查
采用西門子64層雙源SOMATOM Definition Flash dual-source螺旋CT。血栓定義為左心房及左心耳內(nèi)在早期相、晚期相均出現(xiàn)局部充盈缺損,但區(qū)別于梳狀肌影像。見(jiàn)圖2。
圖2 左心房CT血管造影(Multidetector computed tomography,MDCT)技術(shù)
1.4 統(tǒng)計(jì)方法
運(yùn)用SPSS 16.0統(tǒng)計(jì)學(xué)軟件包進(jìn)行統(tǒng)計(jì)學(xué)處理。計(jì)量資料以均數(shù)±標(biāo)準(zhǔn)差()表示。線性趨勢(shì)χ2檢驗(yàn)分析CHA2DS2-VASc評(píng)分與LA/LAA血栓形患病率關(guān)系;以TEE為金標(biāo)準(zhǔn),計(jì)算MDCT敏感度、特異度、陽(yáng)性預(yù)測(cè)值、陰性預(yù)測(cè)值。配對(duì)樣本的χ2檢驗(yàn)(McNemar法)分析TEE與MDCT檢測(cè)Nonvalvular AF患者LA/LAA血栓的差異,以P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
2.1 患者一般臨床資料
不同CHA2DS2-VASc評(píng)分分組病例臨床特征,詳見(jiàn)表1。
2.2 CHA2DS2-VASc評(píng)分各分組血栓發(fā)生率分析
詳見(jiàn)表2。該研究LA/LAA血栓形成13例,陽(yáng)性率5.58%(13/233)。P=0.001,CHA2DS2-VASc評(píng)分越高,LA/LAA血栓形成風(fēng)險(xiǎn)趨大。
表2 CHA2DS2-VASc評(píng)分各組血栓形成分布
2.3 TEE及左心房MDCT檢測(cè)LA/LAA血栓形成對(duì)比分析
TEE檢測(cè)出有血栓患者8例,左心房MDCT發(fā)現(xiàn)3例左心房/左心耳血栓。McNemar法χ2檢驗(yàn)P=0.062,差異無(wú)統(tǒng)計(jì)學(xué)意義。以TEE為金標(biāo)準(zhǔn),左心房MDCT檢測(cè)LA/LAA血栓形成敏感度 SEN=37.5%(3/8),特異度SPE=100%(100/100),陽(yáng)性預(yù)測(cè)值+PV=100%(3/3),陰性預(yù)測(cè)值-PV=95.2%(100/105)。見(jiàn)表3。
表3 MDCT與TEE兩種方法檢測(cè)LA/LAA血栓對(duì)比分析
基于肺靜脈電隔離房顫消融術(shù)式,為根治房顫帶來(lái)希望,特別對(duì)于陣發(fā)性房顫病例,長(zhǎng)期隨訪成功率達(dá)80%[3]。術(shù)前TEE或左心房MDCT檢查可排除LA/LAA血栓形成,是否所有房顫消融術(shù)患者特別是CHA2DS2-VASc 0分、1分均需行TEE及MDCT檢查值得探討。Leif Fbriberg等[4]140420例回顧性研究中發(fā)現(xiàn)CHA2DS2-VASc 1分的房顫且未接受華法林等抗凝治療病例年缺血性卒中、TIA、肺栓塞發(fā)生率為0.5%~0.9%,該類低?;颊呖鼓委熆赡鼙状笥诶?。該文探討新CHA2DS2-VASc評(píng)分與擬接受消融治療房顫病例LA/LAA血栓形成相關(guān)性。
3.1 該研究主要發(fā)現(xiàn)
3.1.1 CHA2DS2-VASc評(píng)分與Nonvalvular AF患者LA/LAA血栓形成顯著相關(guān)性 該研究LA/LAA血栓形成陽(yáng)性率5.6%(13/233),線性趨勢(shì)χ2檢驗(yàn)分析提示CHA2DS2-VASc評(píng)分與LA/LAA血栓形成有明顯統(tǒng)計(jì)學(xué)意義,CHA2DS2-VASc評(píng)分越高,LA/LAA血栓形成風(fēng)險(xiǎn)趨大。CHA2DS2-VASc評(píng)分0分組僅1例(1/ 60,1.7%),1分組2例(2/79,2.5%),CHA2DS2-VASc積分低危0、1分組血栓形成率極低。與國(guó)內(nèi)外研究結(jié)論一致。Decker等[5]643例樣本回顧性研究中CHADS2評(píng)分為0分房顫病例未發(fā)現(xiàn)LA/LAA血栓形成。Puwanant等[6]回顧性研究1058例房顫患者CHADS2評(píng)分為0預(yù)行環(huán)肺射頻消融術(shù)前TEE檢查均未發(fā)現(xiàn)LA/LAA血栓形成。提示CHADS2評(píng)分與LA/LAA血栓形成密切相關(guān)。低?;颊撸–HA2DS2-VASc 0分、1分組)消融或復(fù)律前是否需要行TEE/MDCT排除LA/LAA血栓形成,臨床實(shí)踐亦尚存爭(zhēng)議。該組病例是否免于TEE/MDCT篩查L(zhǎng)A/ LAA血栓直接行消融術(shù)治療,需要更大規(guī)模前瞻性隨機(jī)頭對(duì)頭對(duì)比研究及衛(wèi)生經(jīng)濟(jì)學(xué)風(fēng)險(xiǎn)-獲益比分析。
3.1.2 左房MDCT技術(shù)及TEE檢測(cè)LA/LAA血栓形成對(duì)比分析 該研究對(duì)108例預(yù)行房顫射頻消融患者同時(shí)行TEE和左心房MDCT篩查L(zhǎng)A/LAA血栓。以TEE為金標(biāo)準(zhǔn),左心房MDCT敏感度、特異度、陽(yáng)性預(yù)測(cè)值、陰性預(yù)測(cè)值為 37.5%、100%、100%、95.2%。左心房MDCT提示LA/LAA血栓時(shí),TEE亦均能檢出血栓,5例TEE疑為血栓MDCT卻為陰性,即左心房MDCT存在漏診可能。Martinez M等[7]大樣本(402例)研究顯示64層螺旋CT檢測(cè)左心房血栓的敏感性、特異性、陽(yáng)性預(yù)測(cè)值和陰性預(yù)測(cè)值分別為100%、92%、23%和100%。對(duì)于LA/LAA血栓探查,左心房MDCT技術(shù)與傳統(tǒng)TEE檢查有較好一致性。Kenneth C等[8]回顧研究了2012-2014因房顫/房撲行消融術(shù)治療病例320例,行左心房CTA或TEE檢查排除左心房血栓,并于術(shù)中使用心腔內(nèi)超聲確認(rèn)。研究中左心房CTA及TEE排除LAA血栓的敏感性、特異性均達(dá)100%。研究期間TEE檢查率由57.5%降至24.0%。事實(shí)上該文前述左心房MDCT檢查漏診5例均為左房云霧狀血流,血栓形成可疑病例,經(jīng)規(guī)范抗凝治療2個(gè)后再進(jìn)行TEE評(píng)估未發(fā)現(xiàn)血栓,仍提示左心房、心耳血流緩慢、渦流狀血流,未再次行左心房MDCT檢查。后續(xù)導(dǎo)管射頻消融術(shù)中左心房、肺靜脈造影未發(fā)現(xiàn)血栓形成,圍手術(shù)期及隨訪期未出現(xiàn)血栓栓塞事件。左心房MDCT技術(shù)是否可完全替代傳統(tǒng)經(jīng)食管TEE檢查需要更進(jìn)一步的前瞻性隨機(jī)對(duì)照研究以確認(rèn)。
CHA2DS2-VASc評(píng)分與 LA/LAA血栓形相關(guān),CHA2DS2-VASc 0分、1分低危組預(yù)行消融術(shù)患者LA/ LAA血栓形成發(fā)生率極低。CHA2DS2-VASc評(píng)分越高血栓形成風(fēng)險(xiǎn)趨大,伴高血壓病、充血性心力衰竭是血栓形成主要危險(xiǎn)因素。左心房MDCT技術(shù)與傳統(tǒng)TEE檢查有較好一致性。
[1]January CT,Wann LS,Alpert JS,et al.2014 AHA/ACC/ HRS guideline for the management of patients with atrial fibrillation:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J]. Circulation,2014,130:2071-2104.
[2]黃從新,張澍,黃德嘉,等.心房顫動(dòng):目前的認(rèn)識(shí)和治療建議—2015.中華心律失常學(xué)雜志,2015,19(5):321-384.
[3] Parkash R,Tang AS,Sapp JL,et al.Approach to the catheter ablation technique of paroxysmal and persistent a-trial fibrillation:a meta-analysis of the randomized controlled trials[J].J Cardiovasc Electrophysiol,2011,22:729-738.
[4]Friberg L,Skeppholm M,Terént A.Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1[J].J Am Coll Cardiol.2015,65 (3):225-232.
[5]Decker JM,Madder RD,Hickman L,et al.CHADS(2)socore is predictive ofleft atrial thrombus on precardioversion transesophageal echocardiography in atrial fibrillationv[J]. Am J Cardiovas Dis,2011,1(2):159-165.
[6]Puwanant S,Varr BC,Shrestha K,et al.Role of the CHADS2 Score in the Evaluation of Thromboembolic Risk inPatientswith AtrialFibrillation UndergoingTransesophageal Echocardiography Before Pulmonary Vein Isolation[J].J Am Coll Cardiol,2009,54:2032-2039.
[7]Martinez M,Kirsch J,Williamson EE,et al.Utility of nongated multidetector computed tomography for detection of left atrial thrombus in patients undergoing catheter ablation of atrial fibrillation[J].J Am Coll Cardiol Img,2009,2:69-76.
[8]Kenneth C.Bilchick,Augustus Mealor,Jorge,et al.Effectiveness of integrating delayed computed tomography angiography imaging for left atrial appendage thrombus exclusion into the care of patients undergoing ablation of atrial fibrillation[J].Heart Rhythm,2016,13(1):12-19.
the Predictive Value of CHA2DS2-VASc Score and MDCT in Left Atrial or Left Atrial Appendage Thrombus Formation with Non-valvular Atrial Fibrillation Patients Undergo CPVA
YANG Zhi-ping1,2,ZHANG Jian-cheng1,2,LIN Ya-zhou1,2,CHEN Jian-quan1,2,WU Mei-qiong,1,2,LIAN Liang-hua1,2,CHEN Lin11,2
1.Fujian province hospital heart two families,Fuzhou,Fujian Province,350001 China;2.Fujian provincial clinical medical university school of medicine,Fuzhou,Fujian Province,350001 China
Objective This study aims to the predictive value of CHA2DS2-VASc scores and MDCT in left atrial/left atrial appendage (LA/LAA)thrombus formation in nonvalvular atrial fibrillation patients undergo circumferential pulmonary vein ablation(CPVA).Methods Group selection all datas were collected from those appointed to CPVA with symptomatic nonvalvular atrial fibrillation between January 2012 to December 2014,including CHA2DS2-VASc Scores,Echocardiography, electrocardiography or Holter,chest X-ray,transesophageal echocardiography(TEE),computed tomography Angiography(MDCT).Patients were divided into thrombus group and non-thrombus group according to TEE and MDCT.We demonstrated the relationship between CHA2DS2-VASc scores and LA/LAA thrombus formation by linear Chi-square test and the frequency differences of each factor of CHA2DS2-VASc scores in the two groups based on X2–test or Fisher exact test.X2-test(McNemarmethod)was applied to the difference in LA/LAAthrombus formation detection between TEE and MDCT,sensitivity,specificity,positivepredictive value and negative predictive value were calculated due to TEE gold standard.Results 13LA/LAA thrombus formation in the study,the morbidity was 2.16%(3/139)in low risk group(CHA2DS2-VASc scores 0,1), while 16.28%(7/43)in score three or over three classification.In linear Chi-square test,it showed a rising LA/LAA thrombus prevalence by the CHA2DS2-VASc score ranks,P=0.001.there were 3 LA/LAA thrombus formation in MDCT examination,while 8 suspected cases by TEE,X2-test(McNemarmethod)do not detect the difference(P=0.062).Conclusion It shows a rising thrombus prevalence by the CHA2DS2-VASc score ranks in NonValvlar AF subjects.the incidence of LA/ LAA thrombus Extremely low in CHA2DS2-VASc score zero,one classification.MDCT seems be equivalent to TEE in LA/ LAA thrombus detection.
Nonvalvular atrial fibrillation;CHA2DS2-VASc scores;Left atrial/left atrial appendage;Multidetector computed tomography;MDCT;Transoesophagealechocardiography;TEE
R4
A
1674-0742(2016)06(b)-0183-05
10.16662/j.cnki.1674-0742.2016.17.183
2016-03-16)
楊志平(1979.3-),男,福建惠安人,碩士研究生,研究方向:心血管內(nèi)科,臨床心臟電生理與起搏 。